Lead investor J.P. Morgan buys shares through underwriter Ladenburg
By Devika Patel
Knoxville, Tenn., Jan. 30 - Navidea Biopharmaceuticals, Inc. said it priced a $4.78 million public offering of stock. The transaction was led by J.P. Morgan Asset Management.
The company sold 1,542,389 common shares at $3.10 per share, a 0.32% discount to the Jan. 29 closing share price of $3.11.
Ladenburg Thalmann & Co. Inc. is the underwriter.
Settlement is expected Feb. 4.
Proceeds will be used to fund Navidea's ongoing operations.
Navidea is a Dublin, Ohio-based biomedical company focused on precision diagnostic radiopharmaceuticals to help identify sites and pathways of undetected disease.
| Issuer: | Navidea Biopharmaceuticals, Inc.
|
| Issue: | Common shares
|
| Amount: | $4,781,406
|
| Shares: | 1,542,389
|
| Price: | $3.10
|
| Warrants: | No
|
| Underwriters: | Ladenburg Thalmann & Co. Inc.
|
| Investors: | J.P. Morgan Asset Management (lead)
|
| Pricing date: | Jan. 30
|
| Settlement date: | Feb. 4
|
| Stock symbol: | NYSE: NAVB
|
| Stock price: | $3.11 at close Jan. 29
|
| Market capitalization: | $338.52 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
